Compare LRHC & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRHC | GCTK |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 1.3M |
| IPO Year | 2022 | 2011 |
| Metric | LRHC | GCTK |
|---|---|---|
| Price | $2.87 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 2.2M |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.17 | N/A |
| EPS | N/A | ★ 31.22 |
| Revenue | ★ $69,448,786.00 | $589,462.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.02 |
| Revenue Growth | ★ 118.67 | N/A |
| 52 Week Low | $0.08 | $0.09 |
| 52 Week High | $11.21 | $15.90 |
| Indicator | LRHC | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 83.95 | 37.91 |
| Support Level | $0.51 | $0.62 |
| Resistance Level | $6.39 | $1.00 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.27 | 0.04 |
| Stochastic Oscillator | 93.43 | 29.67 |
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.